GAITHERSBURG, Md., July 26, 2021 /PRNewswire/ -- MaxCyte, Inc.,
(LSE: MXCT) (LSE: MXCN), a leading provider of platform
technologies for cell engineering, today announced the commencement
of an underwritten offering of 12,000,000 shares of common stock
(the "Offering") at an expected offering price between
$11.50 and $13.50 per share. All shares to be sold in the
Offering will be offered by MaxCyte. In addition, MaxCyte intends
to grant the underwriters a 30-day option to purchase up to
1,800,000 additional shares of common stock.
MaxCyte has applied to have its common stock listed on the
Nasdaq Global Market ("Nasdaq") under the symbol
"MXCT." Upon completion of the Offering, MaxCyte's common stock
will continue to be admitted to trading on the AIM market of the
London Stock Exchange (the "AIM") under the symbols "MXCT"
and "MXCN." Application will be made for the shares of common stock
to be issued at the closing of the Offering to be admitted to
trading on AIM.
Cowen, Stifel and William Blair
are acting as joint book-running managers for the Offering and as
representatives of the underwriters for the Offering. BTIG and
Stephens Inc. are also acting as co-managers of the Offering.
The Offering will be made only by means of a prospectus. Copies
of the preliminary prospectus relating to and describing the terms
of the Offering may be obtained from the offices of Cowen and
Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, New York 11717,
Attn: Prospectus Department, by telephone at (833) 297-2926 or by
email at PostSaleManualRequests@broadridge.com; Stifel, Nicolaus
& Company, Incorporated, Attention: Prospectus Department,
One Montgomery Street, Suite 3700,
San Francisco, CA 94104, by
telephone at +1 (415) 364-2720 or by email at
syndprospectus@stifel.com; or William
Blair & Company, L.L.C., Attention: Prospectus
Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at
1-800-621-0687 or by email at prospectus@williamblair.com.
A registration statement relating to these securities has been
filed with the SEC, but has not yet become effective. These
securities may not be sold, nor may offers to buy these securities
be accepted, prior to the time the registration statement becomes
effective. This press release shall not constitute an offer to sell
or the solicitation of an offer to buy these securities, nor shall
there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities law of any
such state or jurisdiction.
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization. MaxCyte's existing
customer base ranges from large biopharmaceutical companies —
including all of the top 10, and 20 of the top 25, pharmaceutical
companies based on 2020 global revenue — to hundreds of
biotechnology companies and academic centers focused on
translational research. MaxCyte has granted 13 strategic platform
licenses to commercial cell therapy developers covering more than
75 programs under clinical licenses that are part of the strategic
platform licenses. MaxCyte was founded in 1998 and is headquartered
in Gaithersburg, Maryland, US.
MaxCyte Contacts:
MaxCyte Contacts:
MaxCyte Inc.
Doug
Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial
Officer
+1-301-944-1660
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl /
Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James
Black / Duncan Monteith /
Matthew O'Dowd
+44 (0)20 7260 1000
Joint Corporate Broker
Stifel Nicolaus Europe Limited
Healthcare Investment
Banking
Nicholas Moore / Ben Maddison / Samira Essebiyea
Corporate Broking
Nick Adams
+44 (0)20 7710 7600
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
US IR Adviser
Gilmartin Group
David
Deuchler, CFA
david@gilmartinir.com
Forward-Looking Statements
Certain statements made in this press release are
forward-looking statements including with respect to the Offering.
These forward-looking statements are not historical facts but
rather are based on the Company's current expectations, estimates,
and projections about its industry; its beliefs; and assumptions.
Words such as "anticipates," "expects," "intends," "plans,"
"believes," "seeks," "estimates" and similar expressions are
intended to identify forward-looking statements. These statements
are not guarantees of future performance and are subject to known
and unknown risks, uncertainties, and other factors, some of which
are beyond the Company's control, are difficult to predict, and
could cause actual results to differ materially from those
expressed or forecasted in the forward-looking statements,
including if the Company's registration statement is not declared
effective by the SEC, if Nasdaq fails to approve the Company's
common stock listing application or if there are adverse market or
economic conditions. The Company cautions security holders and
prospective security holders not to place undue reliance on these
forward-looking statements, which reflect the view of the Company
only as of the date of this press release. The forward-looking
statements made in this press release relate only to events as of
the date on which the statements are made. The Company will not
undertake any obligation to release publicly any revisions or
updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
View original
content:https://www.prnewswire.com/news-releases/maxcyte-announces-launch-of-offering-and-application-to-list-on-the-nasdaq-global-market-301340920.html
SOURCE MaxCyte, Inc.